Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G von Herrath

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Journal of Neuroimmunology|June 16, 2000
Obstacles to identifying viruses that cause autoimmune diseaseM G von Herrath
Novartis Foundation Symposium|September 1, 2001
Design of immune-based interventions in autoimmunity and viral infections--the need for predictive models that integrate time, dose and classes of immune responsesM G von Herrath
Clinical and Experimental Immunology|January 18, 2011
Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) modelD Bresson, M G von Herrath
The Journal of Experimental Medicine|February 3, 1997
Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitusM G von Herrath, M B Oldstone
Trends in Microbiology|November 1, 1995
Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseasesM G von Herrath, M B Oldstone
Clinical and Experimental Immunology|April 27, 2010
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: viruses, autoimmunity and immunoregulationC M Filippi, M G von Herrath
The Journal of Pathology|December 29, 2007
IL-10 and the resolution of infectionsC M Filippi, M G von Herrath
Annals of Medicine|August 19, 2000
DNA vaccination to treat autoimmune diabetesM G von Herrath, J L Whitton
Current Opinion in Immunology|December 1, 1996
Virus-induced autoimmune diseaseM G von Herrath, M B Oldstone
Journal of Autoimmunity|May 4, 2001
Tolerance induction with agonist peptides recognized by autoaggressive lymphocytes is transient: therapeutic potential for type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvantM G von Herrath, B Coon, T Wolfe
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Journal of Neuroimmunology|June 16, 2000
Obstacles to identifying viruses that cause autoimmune diseaseM G von Herrath
Novartis Foundation Symposium|September 1, 2001
Design of immune-based interventions in autoimmunity and viral infections--the need for predictive models that integrate time, dose and classes of immune responsesM G von Herrath
Clinical and Experimental Immunology|January 18, 2011
Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) modelD Bresson, M G von Herrath
The Journal of Experimental Medicine|February 3, 1997
Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitusM G von Herrath, M B Oldstone
Trends in Microbiology|November 1, 1995
Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseasesM G von Herrath, M B Oldstone
Clinical and Experimental Immunology|April 27, 2010
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: viruses, autoimmunity and immunoregulationC M Filippi, M G von Herrath
The Journal of Pathology|December 29, 2007
IL-10 and the resolution of infectionsC M Filippi, M G von Herrath
Annals of Medicine|August 19, 2000
DNA vaccination to treat autoimmune diabetesM G von Herrath, J L Whitton
Current Opinion in Immunology|December 1, 1996
Virus-induced autoimmune diseaseM G von Herrath, M B Oldstone
Journal of Autoimmunity|May 4, 2001
Tolerance induction with agonist peptides recognized by autoaggressive lymphocytes is transient: therapeutic potential for type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvantM G von Herrath, B Coon, T Wolfe
Pageof 5